Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  10.00 0.82% 1,224.00 397,382 16:35:07
Bid Price Offer Price High Price Low Price Open Price
1,219.00 1,223.00 1,240.00 1,198.00 1,211.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 260.00 8.40 6.00 204.0 2,646
Last Trade Time Trade Type Trade Size Trade Price Currency
18:28:26 O 51,909 1,212.635 GBX

Abcam (ABC) Latest News (1)

More Abcam News
Abcam Takeover Rumours

Abcam (ABC) Discussions and Chat

Abcam Forums and Chat

Date Time Title Posts
27/7/202010:49ABCAM with Charts & News180
19/11/201720:07Investing ? Start with your ABC's703
29/8/201323:08ABCAM - another e-Commerce Retailer120

Add a New Thread

Abcam (ABC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Abcam trades in real-time

Abcam (ABC) Top Chat Posts

Abcam Daily Update: Abcam Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ABC. The last closing price for Abcam was 1,214p.
Abcam Plc has a 4 week average price of 1,142p and a 12 week average price of 1,142p.
The 1 year high share price is 1,584p while the 1 year low share price is currently 943p.
There are currently 216,192,416 shares in issue and the average daily traded volume is 344,131 shares. The market capitalisation of Abcam Plc is £2,646,195,171.84.
bathcoup: Issue of Shares to Durable Capital Partners LP at an issue price of 1,100 pence per share. 09/04/2020 5:33pm, UK Regulatory (RNS & others)
erogenous jones: Not often a share price rises on Ex-Dividend date, but not complaining. Looks as if I was way off the mark in my last post. China is getting back to work, so I suspect that the UK will follow suit in June or thereabouts
mw8156: significant fall in the share price might result in it being taken over as the leading antibody company, their cash generative nature and their huge catalogue of 18000 validated antibodies and that would be Britain's only leading life sciences tools company disappearing which would be a shame after Illumina snapped up our sequencing technology.
erogenous jones: City did not like the figures. Sharp rises and sharp falls (in the share price) are normal for this company.
erogenous jones: Not in the least fussed about the drop yesterday, or the rise today, for that matter. Good, well managed and profitable company that has a track record of share price growth over many years. That was the case last week and remains the case this week. My average price is £6.50 and until the company ceases to be as profitable as in previous years I see no reason why I should not allow profits to run.
jurgenklopp: With regards to the large PDMR purchase yesterday it should be noted that Milner sold over 1 million shares at £14.41 as recently as late September. However re-investing 2 million quid back in company shares ought to provide some kind of support to the share price in these strange times !!
shawzie: I can only agree with Panmure that the current share price overvalues this Company. Earnings fairly static on increasing turnover. Intangibles increasing rapidly, but not reflected in increased earnings. Increase in Net Worth of Company due mainly to increase in Intangibles. Does anyone have a more optimistic view?
campbed: Very good trading update today outlining progress on all fronts. A great British success story . Share price at 640p almost back to the all time high of 660p reached at end of 2015 before the market-wide Jan sell off.
apad: Slater in the Telegraph today - with any luck that should drive the share price down for those who are looking for an entry point. apad  . .R01;and some can be disastrous Other Aim shares that are favourites of veteran IHT investors are Young & Co’s Brewery, Advanced Medical Solutions and Abcam. All three are good sound companies but it seems to me that their share prices are living on the memory of their excellent past growth. Nowadays their p/e ratios are in or around the 20s with only single-digit earnings growth forecast. They are not for me because the slightest upset in their earnings growth could cause a major setback in their shares.
richscotsman: Buy into Abcam as share price drops, says Numis Antibody supplier Abcam (ABC.L) has been upgraded from 'hold' to 'buy' by Numis analyst Charles Weston. Weston placed a target price of 510p on the shares despite a sharp drop in the share price earlier in the week as it revealed sluggish Japanese growth despite the Japanese government investing in research. 'We are upgrading our recommendation to 'buy', from 'hold', following the sharp fall in the share price [on Wednesday morning],' he said. 'In our view little has changed in the fundamental investment thesis for Abcam and history has taught us that periods of weakness in its share price are the right time to buy into its highly defensive business model.' Weston said he 'expected margins and cash generation to remain high due to the characteristics of the product and Abcam's digital platform' and that management's investment in new growth initiatives has 'yet to translate to accelerating growth rates, which could start to be delivered over the next six-12 months'.
Abcam share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200925 18:05:42